证券代码：000710 证券简称：贝瑞基因 公告编号：2025-054 成都市贝瑞和康基因技术股份有限公司 二、审议情况 1、审议通过《2025年第三季度报告》 表决结果：7票同意，0票反对，0票弃权。 第十届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十八次会议于2025年10月30日在北京市昌平区生命园路4号院5号楼8层会议室 以现场与通讯会议相结合的方式召开，会议通知已于2025年10月27日以邮件形式 发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。本次董 事会会议应出席董事7名，实际出席会议董事7名，会议由董事长高扬先生主持， 董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 具体内容详见公司同日在巨潮资讯网披露的《关于变更证券事务代表的公 告》。 董事会认真审阅了《2025年第三季度报告》，认为其内容真实、准确、完整， 不存在任何的虚假记载、误导性陈述或者重 ...

Group 1 - Berry Genomics announced the resignation of its securities affairs representative, Song Xiaofeng, due to the expiration of her contract, and appointed Wang Yidi as the new representative effective October 30, 2025 [1] - For the first half of 2025, Berry Genomics reported that its revenue was entirely derived from the genetic testing industry, with a 100.0% contribution [2] - As of the latest update, Berry Genomics has a market capitalization of 4.5 billion yuan [3]

Core Insights - Berry Genomics reported a third-quarter revenue of 238 million yuan, representing a decline of 12.06% [1] - The company experienced a net loss of 25.32 million yuan in the third quarter, a significant decrease of 2,355.45% [1] - For the first three quarters, revenue totaled 686 million yuan, down 16.65% year-on-year [1] - The net loss for the first three quarters reached 52.56 million yuan, an increase of 606.13% compared to the previous year [1]

Financial Performance - The company's revenue for Q3 2025 was ¥238,222,453.79, representing a decrease of 12.06% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥25,321,174.92, a significant decline of 2,355.45% year-on-year[5]. - The basic earnings per share for the period was -¥0.0716, reflecting a decrease of 2,337.50% compared to the previous year[5]. - Total operating revenue decreased to ¥685,656,794.86 from ¥822,664,528.62, representing a decline of approximately 16.67% year-over-year[21]. - Net profit for the period was a loss of ¥50,421,996.34, compared to a profit of ¥13,944,517.00 in the previous period, indicating a significant downturn[22]. - The company's operating profit turned negative at ¥-42,124,510.87, compared to a positive operating profit of ¥27,346,425.46 in the prior year[22]. - Basic and diluted earnings per share were both ¥-0.1487, a decrease from ¥0.0294 in the previous period[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,343,710,762.08, down 1.72% from the end of the previous year[5]. - Total current assets decreased from 1,439,086,278.92 CNY to 1,298,059,150.34 CNY, a reduction of approximately 9.8%[17]. - Cash and cash equivalents decreased from 383,071,864.35 CNY to 309,746,339.92 CNY, a decline of about 19.2%[17]. - Total non-current assets increased from 945,637,715.14 CNY to 1,045,651,611.74 CNY, an increase of about 10.6%[18]. - Total liabilities increased to ¥694,434,225.54 from ¥669,562,176.39, marking an increase of about 3.00%[22]. - Total equity attributable to shareholders decreased to ¥1,619,622,588.29 from ¥1,679,476,362.94, a decline of approximately 3.57%[22]. Cash Flow - The cash flow from operating activities showed a net outflow of -¥24,582,830.89, a decline of 207.34% compared to the same period last year[11]. - Cash flow from operating activities was ¥759,679,533.20, down from ¥821,350,091.16, reflecting a decline of approximately 7.51% year-over-year[25]. - Net cash flow from operating activities was -$24.58 million, a decrease from $22.90 million in the previous period[26]. - Total cash inflow from investment activities was $15.56 million, down from $309.50 million[26]. - Cash outflow from investment activities totaled $69.82 million, compared to $247.63 million previously[26]. - Net cash flow from financing activities was $23.14 million, a significant improvement from -$198.51 million[27]. - The ending cash and cash equivalents balance was $300.55 million, compared to $201.54 million at the end of the previous period[27]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 64,711[13]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.45% of shares, totaling 44,002,000 shares, which are frozen and pledged[13]. Research and Development - Research and development expenses increased by 34.67% to ¥78,716,866.22, indicating a focus on innovation[10]. - The company reported a significant increase in research and development expenses to ¥78,716,866.22 from ¥58,453,739.70, an increase of about 34.67% year-over-year[22]. - The company is focusing on the development of AI-driven genetic testing technology through its collaboration with the new joint venture[15]. Investments and Joint Ventures - Investment income rose by 168.40% to ¥4,650,790.35, attributed to increased returns from joint ventures[10]. - The company recorded a fair value change gain of ¥2,203,689.24, a turnaround from a loss in the previous year[10]. - The company has established a joint venture, Henan Yuanmeng Kangtong Gene Technology Co., Ltd., to provide integrated testing services for genetic diseases in newborns and children[15]. Other Financial Metrics - Total operating costs decreased to ¥713,217,299.16 from ¥765,979,082.06, a reduction of about 6.89% year-over-year[22]. - Deferred income tax liabilities rose to ¥25,796,262.41 from ¥24,895,474.67, an increase of approximately 3.63%[22]. - Short-term borrowings increased from 113,415,839.27 CNY to 152,448,975.65 CNY, an increase of about 34.4%[18]. - The company experienced a 215.93% increase in lease liabilities, totaling ¥136,604,120.59, due to new leasing agreements[10]. - The company reported a significant increase in receivables, with a 354.19% rise in notes receivable to ¥11,750,786.08[10].

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-055 2025 年 8 月 20 日，成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因""公司"）召开第十届董事会第十六次会议审议通过了《关于为 全资子公司提供担保的议案》，贝瑞基因全资子公司杭州贝瑞和康基因诊断技 术有限公司（以下简称"杭州贝瑞"）向杭州联合农村商业银行股份有限公司 高沙支行（以下简称"杭州联合农商行"）申请综合授信 4,000 万元，授信期 限 1 年。公司同意为杭州贝瑞使用上述授信所形成的债务提供连带责任保证担 保。公司已与杭州联合农商行签订了《最高额保证合同》，具体内容详见公司 于 2025 年 8 月 30 日在巨潮资讯网上披露的《关于为全资子公司提供担保的进 展公告》（公告编号：2025-046）。 近日，为合理降低融资成本，杭州市融资担保集团有限公司（以下简称 "融资担保集团"）就上述杭州联合农商行向杭州贝瑞所提供的折合人民币 1,000 万元的最高融资债权本金提供连带责任保证担保；同时，公司就融资担 保集团向杭州贝瑞所提供的保证担保，在最高额人民币 1,000 万元范围内，提 供连带责任保证反担保。公司于 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-056 传真：010-84306824 成都市贝瑞和康基因技术股份有限公司 关于变更证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）董事会于近日 收到通知，公司证券事务代表宋晓凤女士因合同期满，不再担任公司证券事务代 表职务及其他职务。根据《中华人民共和国公司法》（以下简称《公司法》）《公 司章程》等相关规定，该通知自送达公司董事会之日起生效。截至本公告披露日， 宋晓凤女士未持有公司股份，不涉及应履行而未履行完毕的公开承诺。宋晓凤女 士在担任证券事务代表期间勤勉尽责，公司董事会对宋晓凤女士在任职期间为公 司做出的贡献表示衷心感谢！ 2025年10月30日，公司召开第十届董事会第十八次会议，审议通过了《关于 变更证券事务代表的议案》，同意聘任王一迪女士为公司证券事务代表，任期自 董事会审议通过之日起至第十届董事会任期届满之日止。 王一迪女士（简历见附件）已取得深圳证券交易所颁发的《董事会秘书资格 证书》，其任职资格符合《公司法 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-058 成都市贝瑞和康基因技术股份有限公司 关于2025年前三季度计提资产减值准备的公告 根据《企业会计准则》和公司相关会计政策，公司对于以摊余成本计量的金融 资产、以公允价值计量且其变动计入其他综合收益的债务工具投资、租赁应收款、 合同资产和财务担保合同等，以预期信用损失为基础确认损失准备。公司考虑有关 过去事项、当前状况以及对未来经济状况的预测等合理且有依据的信息，以发生违 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所股票上市规则》的相关规定，成都市贝瑞和康基因技术 股份有限公司（以下简称"本公司"或"公司"）依据《企业会计准则》及公司相 关会计政策的规定，将公司 2025 年前三季度计提资产减值准备的具体情况公告如下： 一、本次计提资产减值准备概述 为了真实、准确地反映公司 2025 年前三季度的财务状况和经营成果，公司依据 《企业会计准则》以及公司相关会计政策的规定，对应收账款、其他应收款、在建 工程、固定资产、长期股权投资、存货跌价损失及合同履约成本等各项资产 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-057 成都市贝瑞和康基因技术股份有限公司 关于全资子公司调整产业园租赁事项的公告 2、甲乙双方协商一致，将新投生物科技产业园北区整体园区（即9-13号楼， 含地下车位）用于产教融合基地招商使用，并临时变更部分楼宇的新型工业用地 功能为产教融合基地功能，其中产业园北区10#楼、11#楼整栋及12#楼的3-5层部 分面积约2.5万平方米为原合同（2024-004）项下由乙方租赁部分。现双方经协 商一致，缩减原合同（2024-004）项下租赁面积，乙方不再租赁新投生物科技产 业园10#楼、11#楼整栋及12#楼的3-5层部分面积约2.5万平方米（简称"减租面 积"），并将减租面积调整至甲方控股股东福州滨海临空开发建设有限公司开发 的福州新区生物医药产业园一期，由乙方设立的福建贝瑞和康产业孵化器有限公 司负责承租。双方就拟变更原合同（2024-004）项下的租赁房屋范围事宜约定如 下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、产业园租赁事项概述 成都市贝瑞和康基因技术股份有限公司（以下简称" ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-059 成都市贝瑞和康基因技术股份有限公司 第十届监事会第十一次会议决议。 第十届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第十一次会议于 2025 年 10 月 30 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2025 年 10 月 28 日以邮件形式发 送给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事 会会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生 主持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 二、审议情况 1、审议通过《2025 年第三季度报告》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会审阅了《2025 年第三季度报告》，认为其内容真实、准确、完整， 不存在任何的虚假记载、误导性陈述或者 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]